



NextFerm Technologies announces filing a patent for ProteVin™, its vegan protein, which protects the protein composition and production process

(Yokneam Illit, October 24, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative is strengthening the product's IP – Announces today the filing of a European patent for protection of the protein composition and production process. This is the initial phase for the international registration of the patent.

The filing for patent registration is part of the company's strategy for strengthening its commercial advantage and position in the market, among others, by filing for patents and preserving its proprietary knowledge.

The company launched ProteVin™ and started marketing and supplying purchase orders during the second quarter of 2022.

In September 2022 the Company announced a strategic manufacturing agreement for the production of ProteVin™ with a subcontractor in the Balkan region in Europe, which is expected to replace the current pilot production plant in GFR Canada. The manufacturing plant will enable, at first stage, the production of ProteVin™ with an annual capacity of up to \$10M starting the second half of 2023. The plant commissioning plan enables a future expansion of the capacity to tens millions of dollars.

About NextFerm Technologies

NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives.

NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. The company launched ProteVin™ and started marketing and supplying purchase orders during the second quarter of 2022.

Another product currently being sold is Astaferm[®], an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada.

The company has additional products which have been licensed to Lallemand, a global giant focused on yeast.

For more information, visit the NextFerm website at: www.nextferm.com

Legal Notice Regarding Forward-Looking Statements

This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company's control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company's operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company's current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company's operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors.

For additional information:

Investor and Media Contact

Meirav Gomeh-Bauer

Investor Relations & Financial Media

+972-54-4764979

Meirav@bauerg.com